<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://riskpublishing.com/wp-content/plugins/pretty-rss-feeds/xslt/pretty-feed.xsl" type="text/xsl" media="screen" ?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Data Integrity Risk Assessment &#8211; Risk Publishing</title>
	<atom:link href="https://riskpublishing.com/tag/data-integrity-risk-assessment/feed/" rel="self" type="application/rss+xml" />
	<link>https://riskpublishing.com</link>
	<description>Connecting Risk Professionals</description>
	<lastBuildDate>Thu, 14 May 2026 16:34:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://riskpublishing.com/wp-content/uploads/2021/12/cropped-favicon2-32x32.png</url>
	<title>Data Integrity Risk Assessment &#8211; Risk Publishing</title>
	<link>https://riskpublishing.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Data Integrity Risk Assessment: A 2026 GxP Decision Framework for US Pharma</title>
		<link>https://riskpublishing.com/data-integrity-risk-assessment/</link>
					<comments>https://riskpublishing.com/data-integrity-risk-assessment/#respond</comments>
		
		<dc:creator><![CDATA[Chris Ekai]]></dc:creator>
		<pubDate>Thu, 20 Jul 2023 09:56:27 +0000</pubDate>
				<category><![CDATA[Risk Assessment]]></category>
		<category><![CDATA[Data Integrity Risk Assessment]]></category>
		<category><![CDATA[risk assessment]]></category>
		<guid isPermaLink="false">https://riskpublishing.com/?p=18127</guid>

					<description><![CDATA[In June 2024 the FDA issued a warning letter to Aurobindo&#8217;s Eugia Pharma Specialities Unit-III formulation site after an Official Action Indicated inspection. The findings landed where they always land: incomplete batch records, audit trails that nobody reviewed, and a Quality Unit that could not produce evidence of an effective Data Integrity Risk Assessment. Aurobindo ... <a title="Data Integrity Risk Assessment: A 2026 GxP Decision Framework for US Pharma" class="read-more" href="https://riskpublishing.com/data-integrity-risk-assessment/" aria-label="Read more about Data Integrity Risk Assessment: A 2026 GxP Decision Framework for US Pharma">Read more</a>]]></description>
		
					<wfw:commentRss>https://riskpublishing.com/data-integrity-risk-assessment/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
